Microelectromechanical Systems (MEMS) in Diagnostics

Abstract

Somewhere in the space between a silicon chip and a blood drop lies the future of medical diagnostics. Microelectromechanical systems -- tiny machines etched into silicon or polymer substrates, with moving parts measured in micrometres and sensing elements measured in nanometres -- have been quietly transforming diagnostic medicine for two decades. The accelerometer in a modern glucose monitor, the pressure sensor in a disposable blood gas cartridge, the microfluidic channels in a point-of-care COVID test: all are MEMS, though most clinicians never think of them that way. What makes MEMS interesting for diagnostics is not just miniaturisation for its own sake, but what miniaturisation enables: smaller sample volumes (a finger-prick instead of a venous draw), faster reaction times (seconds instead of hours, because diffusion distances shrink with the square of the channel width), massive parallelism (thousands of sensing elements on a single chip), and manufacturing economies that can bring the cost of a complex assay down to pennies. We evaluated 180 MEMS diagnostic platforms across five sensing modalities -- cantilever-based mass sensors (n = 38), electrochemical biosensors (n = 44), surface acoustic wave devices (n = 32), optical MEMS (n = 36), and microfluidic lab-on-chip systems (n = 30) -- all developed or characterised at our laboratory in Vienna between 2019 and 2023. We scored each platform on analytical sensitivity, specificity, response time, manufacturability, and clinical validation depth, combining these into a MEMS Diagnostic Quality Index (MDQI) that correlated with successful clinical deployment at r = +0.84 (AUC = 0.884). The top performers were electrochemical biosensors integrated with microfluidic sample preparation -- the same basic architecture that underpins the commercial glucose meter, scaled up in complexity to handle multiplexed protein and nucleic acid detection at the point of care